Abstract | INTRODUCTION: METHODS: One hundred thirty-five subjects (78 men and 57 women; age: 62 ± 10 years) naïve to incretin-based therapies were treated with low-dose liraglutide (1.2 mg/day) as an add-on to metformin for 18 months. Patients were divided into two subgroups based on their body-mass index (BMI): (a) obese (BMI ≥ 30) and (b) non-obese (BMI < 30). Clinical and laboratory analyses were assessed at baseline and every 6 months. RESULTS: CONCLUSION:
Liraglutide had beneficial actions on glycemic parameters and cardiometabolic risk factors in both non-obese and obese patients with T2DM, with a greater efficacy in the latter. These findings reinforce the benefits of liraglutide for the cardiometabolic outcomes of obese patients with T2DM in the real-world setting. This has critical importance during the current pandemic, since patients with diabetes and obesity are exposed globally to the most severe forms of COVID-19, related complications, and death. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01715428.
|
Authors | Dragana Nikolic, Angelo M Patti, Rosaria V Giglio, Roberta Chianetta, Giuseppa Castellino, Antonio Magán-Fernández, Roberto Citarrella, Nikolaos Papanas, Andrej Janez, Anca Pantea Stoian, Ali A Rizvi, Manfredi Rizzo |
Journal | Diabetes therapy : research, treatment and education of diabetes and related disorders
(Diabetes Ther)
Vol. 13
Issue 3
Pg. 453-464
(Mar 2022)
ISSN: 1869-6953 [Print] United States |
PMID | 35167051
(Publication Type: Journal Article)
|
Copyright | © 2022. The Author(s). |